Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term

Zacks Investment Research highlights AstraZeneca (AZN) as a potentially attractive momentum stock, noting its B Momentum Style Score and a 1.2% share price increase over the past four weeks. While AZN holds a Zacks Rank of #3 (Hold), it boasts a VGM Score of A, and analysts have revised fiscal 2025 earnings estimates upwards to $4.49 per share, reflecting a 4.2% average earnings surprise; Zacks suggests that the combination of a solid Zacks Rank and favorable Style Scores makes AZN worthy of investor consideration.

Analysis

AstraZeneca (AZN) is highlighted by Zacks Investment Research for its momentum characteristics, despite holding a #3 (Hold) Zacks Rank. The company scores an 'A' on the VGM (Value, Growth, Momentum) composite score and a 'B' on its Momentum Style Score, indicating a favorable profile for these factors. This is supported by a 1.2% increase in its share price over the past four weeks. From a fundamentals perspective, two analysts have revised their earnings estimates upwards for fiscal 2025 within the last 60 days, leading to a Zacks Consensus Estimate of $4.49 per share for that period. AstraZeneca also has a track record of positive earnings surprises, averaging 4.2%. While the 'Hold' rank suggests a neutral short-term outlook based on earnings estimate revisions momentum, the strong Style Scores, particularly in Momentum and overall VGM, position AZN as a stock for investors to monitor closely for potential outperformance driven by these specific attributes.

Key Decisions for Investors

• Investors with a focus on momentum strategies should consider AZN due to its 'B' Momentum Style Score and recent positive price action, supported by upward revisions in fiscal 2025 earnings estimates.
• While the Zacks Rank is #3 (Hold), the strong 'A' VGM Score suggests that AZN may offer a compelling combination of value, growth, and momentum attributes that warrant further due diligence.
• Monitor future earnings estimate revisions closely, as sustained positive revisions could lead to an upgrade in the Zacks Rank, potentially signaling a stronger buy opportunity; the current 'Hold' rating warrants careful position sizing despite favorable style metrics.